Amyloid-β dimers in the absence of plaque pathology impair learning and synaptic plasticity

Brain

Volumn 139, Issue 2, 2016, Pages 509-525

  Müller Schiffmann, Andreas ^a   Herring, Arne ^b   Abdel Hafiz, Laila ^a   Chepkova, Aisa N ^a   Schäble, Sandra ^a   Wedel, Diana ^a   Horn, Anselm H C ^c   Sticht, Heinrich ^c   De Souza Silva, Maria A ^a   Gottmann, Kurt ^a   Sergeeva, Olga A ^a   Huston, Joseph P ^a   Keyvani, Kathy ^b   Korth, Carsten ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Abeta; Alzheimer's disease; dimer; disulphide engineering; mouse model; oligomer; seed

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CYSTEINE; DIMER; MONOMER; OLIGOMER; RECOMBINANT PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS BREEDING; EXPRESSION VECTOR; HIPPOCAMPUS; LEARNING DISORDER; LIFESPAN; LONG TERM POTENTIATION; MALE; MOUSE; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; GENETICS; METABOLISM; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; TRANSGENIC MOUSE;

AMYLOID BETA-PEPTIDES; ANIMALS; COGNITION DISORDERS; HIPPOCAMPUS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONAL PLASTICITY; ORGAN CULTURE TECHNIQUES; PLAQUE, AMYLOID; PROTEIN MULTIMERIZATION;

EID: 84959881645     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv355     Document Type: Article

References (83)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421
2. Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurologisches Centralblatt 1906; 23: 1129-36
3. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-9
4. Blair JA, Siedlak SL, Wolfram JA, Nunomura A, Castellani RJ, Ferreira ST, et al. Accumulation of intraneuronal amyloid-beta is common in normal brain. Curr Alzheimer Res 2014; 11: 317-24
5. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59
6. Cai XD, Golde TE, Younkin SG. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 1993; 259: 514-6
7. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000; 408: 975-9
8. Chen Y, Huang X, Zhang YW, Rockenstein E, Bu G, Golde TE, et al. Alzheimer's beta-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of beta-amyloid. J Neurosci 2012; 32: 11390-5
9. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 2007; 282: 23818-28
10. Chepkova A, Yanovsky E, Parmentier R, Ohtsu H, Haas HL, Lin JS, et al. Histamine receptor expression, hippocampal plasticity and ammonia in histidine decarboxylase knockout mice. Cell Mol Neurobiol 2012; 32: 17-25
11. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001; 276: 21562-70
12. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science 2006; 313: 1604-10
13. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995; 16: 285-98; discussion 298-304
14. Dornieden S, Muller-Schiffmann A, Sticht H, Jiang N, Cinar Y, Wordehoff M, et al. Characterization of a single-chain variable fragment recognizing a linear epitope of abeta: a biotechnical tool for studies on Alzheimer's disease?. PLoS One 2013; 8: e59820
15. Hamilton LK, Aumont A, Julien C, Vadnais A, Calon F, Fernandes KJ. Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg mouse model of Alzheimer's disease. Eur J Neurosci 2010; 32: 905-20
16. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6
17. Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J Neurosci 2012; 32: 15181-92
18. Haupt C, Leppert J, Ronicke R, Meinhardt J, Yadav JK, Ramachandran R, et al. Structural basis of beta-amyloid-dependent synaptic dysfunctions. Angew Chem Int Ed Engl 2012; 51: 1576-9
19. Hefti F, Goure WF, Jerecic J, Iverson KS, Walicke PA, Krafft GA. The case for soluble Abeta oligomers as a drug target in Alzheimer's disease. Trends Pharmacol Sci 2013; 34: 261-6
20. Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, et al. Dynamic analysis of amyloid betaprotein in behaving mice reveals opposing changes in ISF versus parenchymal Abeta during age-related plaque formation. J Neurosci 2011; 31: 15861-9
21. Horn AH, Sticht H. Amyloid-beta42 oligomer structures from fibrils: a systematic molecular dynamics study. J Phys Chem 2010; 114: 2219-26
22. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006; 52: 831-43
23. Hu NW, Smith IM, Walsh DM, Rowan MJ. Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. Brain 2008; 131: 2414-24
24. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 2011; 108: 5819-24
25. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, et al. APP processing and synaptic function. Neuron 2003; 37: 925-37
26. Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, et al. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2004; 24: 3801-9
27. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001; 21: 372-81
28. Kinoshita A, Whelan CM, Berezovska O, Hyman BT. The gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells. J Biol Chem 2002; 277: 28530-6
29. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, et al. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 2008; 28: 4231-7
30. Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging 2007; 28: 1297-306
31. Kumar S, Rezaei-Ghaleh N, Terwel D, Thal DR, Richard M, Hoch M, et al. Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. Embo J 2012; 30: 2255-65
32. Lam AR, Rodriguez JJ, Rojas A, Scheraga HA, Mukamel S. Tracking the mechanism of fibril assembly by simulated two-dimensional ultraviolet spectroscopy. J Phys Chem A 2013; 117: 342-50
33. Lisman JE, Raghavachari S, Tsien RW. The sequence of events that underlie quantal transmission at central glutamatergic synapses. Nat Rev Neurosci 2007; 8: 597-609
34. Lu DC, Soriano S, Bredesen DE, Koo EH. Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicity. J Neurochem 2003; 87: 733-41
35. Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R. Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue. Cell 2013; 154: 1257-68
36. Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, et al. Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med 2013; 5: 194re2
37. Marchetti C, Marie H. Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models?. Rev Neurosci 2011; 22: 373-402
38. Matsumura M, Signor G, Matthews BW. Substantial increase of protein stability by multiple disulphide bonds. Nature 1989; 342: 291-3
39. Mc Donald JM, O'Malley TT, Liu W, Mably AJ, Brinkmalm G, Portelius E, et al. The aqueous phase of Alzheimer's disease brain contains assemblies built from approximately 4 and approximately 7 kDa Abeta species. Alzheimers Dement 2015; 11: 1286-305
40. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, et al. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 2010; 133: 1328-41
41. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860-6
42. Mohrmann R, Lessmann V, Gottmann K. Developmental maturation of synaptic vesicle cycling as a distinctive feature of central glutamatergic synapses. Neuroscience 2003; 117: 7-18
43. Morales-Corraliza J, Berger JD, Mazzella MJ, Veeranna, Neubert TA, Ghiso J, et al. Calpastatin modulates APP processing in the brains of beta-amyloid depositing but not wild-type mice. Neurobiol Aging 2013; 33: 1125 e9-18
44. Morris RG, Garrud P, Rawlins JN, O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 1982; 297: 681-3
45. Morrissette DA, Parachikova A, Green KN, LaFerla FM. Relevance of transgenic mouse models to human Alzheimer disease. J Biol Chem 2009; 284: 6033-7
46. Muller-Schiffmann A, Andreyeva A, Horn AH, Gottmann K, Korth C, Sticht H. Molecular engineering of a secreted, highly homogeneous, and neurotoxic abeta dimer. ACS Chem Neurosci 2011; 2: 242-8
47. Muller-Schiffmann A, Marz-Berberich J, Andreyeva A, Ronicke R, Bartnik D, Brener O, et al. Combining independent drug classes into superior, synergistically acting hybrid molecules. Angew Chem Int Ed Engl 2010; 49: 8743-6
48. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362-81
49. Nguyen PH, Li MS, Stock G, Straub JE, Thirumalai D. Monomer adds to preformed structured oligomers of Abeta-peptides by a two-stage dock-lock mechanism. Proc Natl Acad Sci USA 2007; 104: 111-6
50. O'Malley TT, Oktaviani NA, Zhang D, Lomakin A, O'Nuallain B, Linse S, et al. Abeta dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies. Biochem J 2014; 461: 413-26
51. O'Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, et al. Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci 2010; 30: 14411-9
52. Ono K, Condron MM, Teplow DB. Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid beta-protein assembly and toxicity. J Biol Chem 2010; 285: 23186-97
53. Pan J, Han J, Borchers CH, Konermann L. Conformer-specific hydrogen exchange analysis of Abeta(1-42) oligomers by top-down electron capture dissociation mass spectrometry. Anal Chem 2011; 83: 5386-93
54. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, et al. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 1995; 270: 9564-70
55. Reed MN, Hofmeister JJ, Jungbauer L, Welzel AT, Yu C, Sherman MA, et al. Cognitive effects of cell-derived and synthetically derived Abeta oligomers. Neurobiol Aging 2011; 32: 1784-94
56. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, et al. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993; 268: 3072-83
57. Rojas A, Liwo A, Browne D, Scheraga HA. Mechanism of fiber assembly: treatment of Abeta peptide aggregation with a coarsegrained united-residue force field. J Mol Biol 2010; 404: 537-52
58. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S. Aminoand carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett 1996; 215: 173-6
59. Scheuermann S, Hambsch B, Hesse L, Stumm J, Schmidt C, Beher D, et al. Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease. J Biol Chem 2001; 276: 33923-9
60. Schlenzig D, Manhart S, Cinar Y, Kleinschmidt M, Hause G, Willbold D, et al. Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry 2009; 48: 7072-8
61. Schmechel A, Zentgraf H, Scheuermann S, Fritz G, Pipkorn R, Reed J, et al. Alzheimer beta-amyloid homodimers facilitate A beta fibrillization and the generation of conformational antibodies. J Biol Chem 2003; 278: 35317-24
62. Schulz D, Huston JP, Jezek K, Haas HL, Roth-Harer A, Selbach O, et al. Water maze performance, exploratory activity, inhibitory avoidance and hippocampal plasticity in aged superior and inferior learners. Eur J Neurosci 2002; 16: 2175-85
63. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008; 192: 106-13
64. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-42
65. Shimaoka M, Lu C, Salas A, Xiao T, Takagi J, Springer TA. Stabilizing the integrin alpha M inserted domain in alternative conformations with a range of engineered disulfide bonds. Proc Natl Acad Sci USA 2002; 99: 16737-41
66. Sisodia SS, Koo EH, Hoffman PN, Perry G, Price DL. Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system. J Neurosci 1993; 13: 3136-42
67. Skaper SD. Alzheimer's disease and amyloid: culprit or coincidence?. Int Rev Neurobiol 2012; 102: 277-316
68. Spires-Jones T, Knafo S. Spines, plasticity, and cognition in Alzheimer's model mice. Neural Plast 2012; 2012: 319836
69. Stewart S, Cacucci F, Lever C. Which memory task for my mouse? A systematic review of spatial memory performance in the Tg2576 Alzheimer's mouse model. J Alzheimers Dis 2011; 26: 105-26
70. Stravalaci M, Beeg M, Salmona M, Gobbi M. Use of surface plasmon resonance to study the elongation kinetics and the binding properties of the highly amyloidogenic Abeta(1-42) peptide, synthesized by depsi-peptide technique. Biosens Bioelectron 2011; 26: 2772-5
71. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997; 94: 13287-92
72. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-80
73. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-800
74. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, et al. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 2010; 30: 4845-56
75. Treusch S, Cyr DM, Lindquist S. Amyloid deposits: protection against toxic protein species?. Cell Cycle 2009; 8: 1668-74
76. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 2003; 17: 388-96
77. Wegiel J, Kuchna I, Nowicki K, Frackowiak J, Mazur-Kolecka B, Imaki H, et al. Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Acta Neuropathol 2007; 113: 389-402
78. Welzel AT, Maggio JE, Shankar GM, Walker DE, Ostaszewski BL, Li S, et al. Secreted amyloid beta-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity. Biochemistry 2014; 53: 3908-21
79. Wirths O, Bayer TA. Intraneuronal Abeta accumulation and neurodegeneration: lessons from transgenic models. Life Sci 2012; 91: 1148-52
80. Yamaguchi T, Yagi H, Goto Y, Matsuzaki K, Hoshino M. A disulfidelinked amyloid-beta peptide dimer forms a protofibril-like oligomer through a distinct pathway from amyloid fibril formation. Biochemistry 2010; 49: 7100-7
81. Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, Oster-Granite ML, Neve RL. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 1989; 245: 417-20
82. Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, et al. Neutralization of soluble, synaptotoxic amyloid beta species by antibodies is epitope specific. J Neurosci 2012; 32: 2696-702
83. Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R, et al. (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2014; 7: CD010386.